Institute of Lung Health and Immunity (LHI) and Comprehensive Pneumology Center (CPC), Helmholtz Munich, Member of the German Center for Lung Research (DZL), 85764, Neuherberg, Germany.
Comprehensive Pneumology Center-Munich (CPC-M) bioArchive, Helmholtz Munich, 81377, Munich, Germany.
Adv Mater. 2022 Oct;34(41):e2205083. doi: 10.1002/adma.202205083. Epub 2022 Sep 11.
Lung fibrosis, one of the major post-COVID complications, is a progressive and ultimately fatal disease without a cure. Here, an organ- and disease-specific in vitro mini-lung fibrosis model equipped with noninvasive real-time monitoring of cell mechanics is introduced as a functional readout. To establish an intricate multiculture model under physiologic conditions, a biomimetic ultrathin basement (biphasic elastic thin for air-liquid culture conditions, BETA) membrane (<1 µm) is developed with unique properties, including biocompatibility, permeability, and high elasticity (<10 kPa) for cell culturing under air-liquid interface and cyclic mechanical stretch conditions. The human-based triple coculture fibrosis model, which includes epithelial and endothelial cell lines combined with primary fibroblasts from idiopathic pulmonary fibrosis patients established on the BETA membrane, is integrated into a millifluidic bioreactor system (cyclic in vitro cell-stretch, CIVIC) with dose-controlled aerosolized drug delivery, mimicking inhalation therapy. The real-time measurement of cell/tissue stiffness (and compliance) is shown as a clinical biomarker of the progression/attenuation of fibrosis upon drug treatment, which is confirmed for inhaled Nintedanib-an antifibrosis drug. The mini-lung fibrosis model allows the combined longitudinal testing of pharmacodynamics and pharmacokinetics of drugs, which is expected to enhance the predictive capacity of preclinical models and hence facilitate the development of approved therapies for lung fibrosis.
肺纤维化是 COVID-19 的主要后遗症之一,是一种进行性的、最终致命的疾病,目前尚无治愈方法。在这里,我们引入了一种器官和疾病特异性的体外肺纤维化模型,该模型具有非侵入性的实时细胞力学监测功能,可作为一种功能读数。为了在生理条件下建立一种复杂的多细胞培养模型,我们开发了一种仿生超薄基底(双相弹性薄基底,BETA)膜(<1 µm),该膜具有独特的性能,包括生物相容性、通透性和高弹性(<10 kPa),可在气液界面和周期性机械拉伸条件下进行细胞培养。基于人类的三重共培养纤维化模型,包括上皮细胞系和内皮细胞系,以及从特发性肺纤维化患者中分离的原代成纤维细胞,建立在 BETA 膜上,整合到一个毫升级的生物反应器系统(周期性体外细胞拉伸,CIVIC)中,该系统具有剂量控制的雾化药物输送,模拟吸入治疗。细胞/组织硬度(和顺应性)的实时测量被作为药物治疗纤维化进展/缓解的临床生物标志物,这一点已通过吸入型尼达尼布(一种抗纤维化药物)得到了验证。该小型肺纤维化模型允许对药物的药效学和药代动力学进行联合纵向测试,有望提高临床前模型的预测能力,从而促进批准用于肺纤维化的治疗方法的发展。